Ctrl K
FBRX trades 0.3% below Wall Street's consensus target of $77.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes FBRX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 9, 2026, Forte Biosciences, Inc. (FBRX) has a Wall Street consensus price target of $77.00, based on estimates from 7 covering analysts. With the stock currently trading at $76.78, this represents a potential upside of +0.3%. The company has a market capitalization of $13.70B.
Analyst price targets range from a low of $77.00 to a high of $77.00, representing a 0% spread in expectations. The median target of $77.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 3 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, FBRX trades at a trailing P/E of -16.3x. Analysts expect EPS to grow -801.6% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ETONEton Pharmaceuticals, Inc. | $1.1B | $41.58 | $59.67 | +43.5% | Buy | 48.4x | 6 |
 PRAXPraxis Precision Medicines, Inc. | $10.8B | $386.33 | $592.00 | +53.2% | Buy | — | 16 |
 SLDBSolid Biosciences Inc. | $892M | $9.06 | $17.00 | +87.5% | Buy | — | 21 |
 TARSTarsus Pharmaceuticals, Inc. | $3.0B | $70.02 | $93.50 | +33.5% | Buy | — | 10 |
 NUVLNuvalent, Inc. | $9.1B | $123.96 | $127.32 | +2.7% | Hold | — | 19 |
 DERMJourney Medical Corporation | $177M | $6.43 | $11.75 | +82.7% | Buy | 98.9x | 3 |
 ACLXArcellx, Inc. | $6.7B | $115.07 | $112.45 | -2.3% | Hold | — | 18 |
 RCKTRocket Pharmaceuticals, Inc. | $372M | $3.41 | $23.81 | +598.2% | Buy | — | 19 |
 KRYSKrystal Biotech, Inc. | $9.8B | $332.86 | $364.50 | +9.5% | Buy | 44.6x | 17 |
 ABBVAbbVie Inc. | $439.3B | $248.66 | $283.92 | +14.2% | Buy | 17.7x | 41 |
Quick answers to the most common questions about buying FBRX stock.
The consensus price target for FBRX is $77, close to the current price of $76.78 (0.3% implied move). Based on 7 analyst estimates, the stock appears fairly valued near current levels.
FBRX has a consensus rating of "Hold" based on 7 Wall Street analysts. The rating breakdown is mixed, with 4 Hold ratings making up the largest segment. The consensus 12-month price target of $77 implies 0.3% upside from current levels.
FBRX's current price is $76.78 with a consensus target of $77 (0.3% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $77 for FBRX, while the most conservative target is $77. The consensus of $77 represents the median expectation. These targets typically reflect 12-month expectations.
FBRX is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 4 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month FBRX stock forecast based on 7 Wall Street analysts shows a consensus price target of $77, with estimates ranging from $77 (bear case) to $77 (bull case). The median consensus rating is "Hold".
FBRX appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $77 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
FBRX analyst price targets range from $77 to $77, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $77 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.